18 recruiting, 15 completed, 15 unknown, 9 terminated. 29 Phase 2, 18 Phase 1, 9 Not applicable, 5 Phase 3, 2 Phase 4.
Follow Minimal Residual Disease: new trials by email Literature Review of Minimal Residual Disease trials Research Report on Minimal Residual Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry Mass spectrometry - Multiple Myeloma, Minimal Residual Disease | Not yet recruiting | Odense University Hospital | 40 | 2026-08-04 | 2026-07-08 | |
| Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients Allogenic expanded Natural Killer Cells (AlloNK1) - Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease | Phase 1 / Phase 2 | Not yet recruiting | Singapore General Hospital | 31 | 2026-04-01 | 2026-03-30 |
| Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial ctDNA-Based Molecular Residual Disease (MRD) Monitoring and Immunoscore Assessment, Neoadjuvant Chemotherapy, Adjuvant chemotherapy - Minimal Residual Disease, Immunoscore | Not applicable | Not yet recruiting | Sun Yat-sen University | 100 | 2026-02-24 | 2026-02-17 |
| Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC Adjuvant PD-1 inhibitors, Active monitoring - HCC, Minimal Residual Disease | Not applicable | Not yet recruiting | Tongji Hospital | 276 | 2025-12-31 | 2026-01-20 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study) Lung Neoplasms, Neoadjuvant Therapy | Recruiting | Peking University People's Hospital | 100 | 2025-05-08 | 2026-03-03 | |
| Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer Minimal Residual Disease, Pancreatic Cancer Resectable | Not yet recruiting | Shanghai Zhongshan Hospital | 66 | 2025-04-20 | 2025-04-24 | |
| Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer Adaptive postoperative management based on minimal residual disease - Non-small Cell Lung Cancer, Minimal Residual Disease | Not applicable | Recruiting | Peking University People's Hospital | 1000 | 2025-03-25 | 2025-04-16 |
| NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL Blinatumomab - B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric | Not applicable | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 1220 | 2025-01-01 | 2025-01-08 |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) Fludarabine Phosphate, Cyclophosphamide, Cetuximab - Colorectal Cancer, Minimal Residual Disease | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2024-12-02 | 2026-08-04 |
| VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 67 | 2024-07-18 | 2024-08-05 |
| Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax MRD assessment - AML, Adult, Minimal Residual Disease | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 225 | 2024-07-01 | 2024-04-10 |
| French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM) Blood sample/Liquid biopsy - Colorectal Cancer, Liver Metastases | Recruiting | University Hospital, Montpellier | 30 | 2024-04-15 | 2026-06-22 | |
| French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) Blood sample/lliquid biopsy - Colorectal Cancer, Stage III Colon Cancer | Recruiting | University Hospital, Montpellier | 70 | 2024-04-11 | 2026-08-18 | |
| Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) Osimertinib, No adjuvant therapy - Lung Cancer, EGFR Gene Mutation | Phase 3 | Not yet recruiting | Fudan University | 226 | 2024-04-01 | 2024-03-21 |
| French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) Blood sample/Liquid Biopsy - Pancreatic Cancer Resectable, Pancreatic Ductal Adenocarcinoma | Recruiting | University Hospital, Montpellier | 37 | 2024-03-01 | 2025-07-10 | |
| Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not Transplant, Autologous, Chemotherapy drug - Multiple Myeloma, Minimal Residual Disease | Recruiting | First Affiliated Hospital of Zhejiang University | 210 | 2023-12-01 | 2024-06-24 | |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease | Recruiting | Personalis Inc. | 422 | 2023-11-09 | 2025-01-07 | |
| A Study of Chidamide With AZA in MRD Positive AML After Transplant chidamide and azacitidine - AML, Adult, Minimal Residual Disease | Not applicable | Recruiting | Guangdong Provincial People's Hospital | 60 | 2023-10-26 | 2023-10-27 |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil Prednisone, Vincristin, Daunorubicin - Acute Lymphoid Leukemia, Minimal Residual Disease | Recruiting | Instituto do Cancer do Estado de São Paulo | 180 | 2023-09-05 | 2025-05-07 |
Showing 20 of 76. Sign in to see all of them.
Neoplasm, Residual (76) · Leukemia, Myeloid, Acute (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Myelodysplastic Syndromes (8) · Colorectal Neoplasms (7) · Colonic Neoplasms (6) · Burkitt Lymphoma (5) · Leukemia, Biphenotypic, Acute (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Lymphoma, Non-Hodgkin (5) · Multiple Myeloma (5) · Recurrence (5) · Carcinoma, Non-Small-Cell Lung (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Hematologic Neoplasms (3)
Neoplastic Processes (76) · Pathologic Processes (76) · Pathological Conditions, Signs and Symptoms (76) · Neoplasms (74) · Neoplasms by Histologic Type (46) · Hemic and Lymphatic Diseases (42) · Hematologic Diseases (40) · Leukemia (34) · Immune System Diseases (26) · Neoplasms by Site (26) · Immunoproliferative Disorders (25) · Lymphoproliferative Disorders (25) · Leukemia, Myeloid (23) · Lymphatic Diseases (22) · Leukemia, Lymphoid (18)
Cyclophosphamide (12) · fludarabine (7) · fludarabine phosphate (7) · Azacitidine (5) · Cytarabine (5) · blinatumomab (5) · Blood Specimen Collection (4) · Melphalan (4) · Imatinib Mesylate (3) · Liquid Biopsy (3) · Whole-Body Irradiation (3) · Busulfan (2) · Clofarabine (2) · Dasatinib (2) · Decitabine (2)
M.D. Anderson Cancer Center (8) · Nanfang Hospital, Southern Medical University (5) · Peking University People's Hospital (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · University Hospital, Montpellier (3) · Beijing 302 Hospital (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Guangdong Provincial People's Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · Stanford University (2) · University Hospital, Clermont-Ferrand (2) · A.O.U. Città della Salute e della Scienza (1) · Caris Science, Inc. (1) · Centre Hospitalier Universitaire de Besancon (1)
United States (28) · China (23) · France (7) · Czechia (2) · Germany (2) · Italy (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Denmark (1) · Mexico (1) · Norway (1) · Poland (1)
Qifa Liu (3) · Antonio Curti (2) · Aaron Goldberg, MD, PhD (1) · Adolfo Martinez Tovar, PhD (1) · Amanda Olson (1) · Amer Zeidan (1) · Arvind Dasari, MD (1) · Blythe Thomson, MD (1) · Christina Peters, MD (1) · Crystal Mackall (1) · Daniel Gomez, MD (1)
PMID 10197236, PMID 10636102, PMID 11215292, PMID 12522257, PMID 12949711, PMID 14515284, PMID 14710949, PMID 15654796, PMID 18076015, PMID 18670422, PMID 2350571, PMID 26311728, PMID 26622800, PMID 27384348, PMID 28054442, PMID 28116786, PMID 28383420, PMID 28445469, PMID 28835441, PMID 28846953, PMID 29388200, PMID 30255106, PMID 30702598, PMID 30957229, PMID 31744224, PMID 31907401, PMID 32027620, PMID 32164760, PMID 32293728, PMID 32519455, PMID 32692850, PMID 32929049, PMID 32934330, PMID 32987138, PMID 33120792, PMID 33204013, PMID 34312556, PMID 34515338, PMID 34889384, PMID 35467818, PMID 35622074, PMID 35713551, PMID 38195752, PMID 38274807, PMID 38683966, PMID 38968138, PMID 40790272, PMID 42439986, PMID 42681647, PMID 7667557
P30CA015704 (2), P30CA016672 (2), K12HL087165 (1), P30CA072720 (1), U10CA180820 (1)